Table 1. General properties of the patients.
NLR: neutrophil to lymphocyte ratio; SII: systemic immune-inflammation index
| N=46 (%) | |||
| Gender (Male) | 25 (54.4%) | ||
| Age (months) | 57.5 (4.14-169.05) | ||
| Complaint | Abdominal mass | 32 (69.6%) | |
| Fever | 2 (4.4%) | ||
| Antenatal | 2 (4.4%) | ||
| Bone pain | 1 (2.2%) | ||
| Thoracal mass | 1 (2.2%) | ||
| Neurologic | 1 (2.2%) | ||
| Vision loss | 1 (2.2%) | ||
| Other | 6 (12.5%) | ||
| Diagnosis | Biopsy | 16 (34.8%) | |
| Clinic-radiologic-bone marrow aspiration | 30 (65.2%) | ||
| Ultrasonography | ≤5 cm | 24 (52.2%) | |
| >5 cm | 22 (47.8%) | ||
| CT | ≤5 cm | 21 (45.7%) | |
| >5 cm | 25 (54.3%) | ||
| PET | SUVmax ≤2.6 | 15 (65.2%) | |
| SUVmax >2.6 | 8 (34.8%) | ||
| Histopathology | Differentiated | 5 (10.9%) | |
| Undifferentiated + poorly differentiated | 18 (39.1%) | ||
| Unknown | 20 (43.5%) | ||
| Intermixed | 3 (6.6%) | ||
| Stage | Early (1,2) | 7 (15.2%) | |
| Advanced (3,4) | 39 (84.8%) | ||
| Metastasis | Present | 29 (63%) | |
| Absent | 17 (37.7%) | ||
| Lymph node involvement | Present | 11 (23.9%) | |
| Absent | 35 (76.1%) | ||
| İnvolvement site | Right | 24 (52.2%) | |
| Left | 19 (41.3%) | ||
| Bilateral | 1 (2.2%) | ||
| Paravertebral | 2 (4.3%) | ||
| Neoadjuvant chemotherapy | Present | 36 (78.3%) | |
| Absent | 10 (21.7%) | ||
| Lymphocyte number | 4390 (940-7630) | ||
| Neutrophil number | 4281 (1170-8430) | ||
| Platelet number | 343.43 (22-890) | ||
| NLR | 1.96 (0.16-5.1) | ||
| SII | 394.57 (69.49-1322) | ||
| Ferritin (ng/ml) | 225.3 (0.4-1322) | ||
| Follow-up (months) | 33.74 (2.76-107.41) | ||
| Mortality | 12 (26.1%) | ||